M281

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis26
46Malignant rheumatoid arthritis2
49Systemic lupus erythematosus4
IDDisease name (Link within this page)Number of trials
53Sjogren syndrome7
61Autoimmune hemolytic anemia11

11. Myasthenia gravis


Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

53. Sjogren syndrome


Clinical trials : 448 / Drugs : 436 - (DrugBank : 104) / Drug target genes : 68 - Drug target pathways : 185 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

61. Autoimmune hemolytic anemia


Clinical trials : 218 / Drugs : 186 - (DrugBank : 42) / Drug target genes : 27 - Drug target pathways : 158 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries